Bioasis Technologies


Market CapC$18m

Last Close C$0.25

Bioasis Technologies is a biopharma company developing the xB3 platform to aid in the delivery of molecules to the brain using receptor mediated transcytosis. The company’s lead program is xB3-001, which is in preclinical development for brain metastases in HER2+ metastatic breast cancer patients.

More Bioasis Technologies content >

Investment summary

Bioasis has a proprietary platform for developing drugs that can pass the blood-brain barrier (BBB) that can be used on small molecules, antibodies, enzymes and other proteins as well as siRNAs. The company has licensed this platform to Prothena, Chiesi and Aposense, as well as advancing its internal development project xB3-001 for the treatment of breast cancer brain metastases.

Y/E Feb
Revenue (C$m)
PBT (C$m)
EPS (c)
P/E (x)
P/CF (x)
2020A 0.6 (4.0) (3.4) (5.50) N/A N/A
2021A 4.1 0.3 0.2 0.01 2500.0 N/A
2022E 3.7 (8.3) (8.3) (11.31) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

Developing a drug to pass the BBB has historically been difficult and limited to small molecules. By developing a modular platform to solve this problem Bioasis is expanding the potential diseases that can be targeted as well as providing a means to re-purpose previously developed drugs to target the brain.

Last updated on 21/09/2021
Content on Bioasis Technologies
Bioasis Technologies – Shifting gears to R&D
Healthcare | Update | 4 November 2020
View more
Register to receive research on Bioasis Technologies as it is published
Share price graph
Balance sheet
Forecast net cash (C$m) 4.1
Forecast gearing ratio (%) N/A
Price performance
Actual (7.3) (21.5) (37.8)
Relative* (6.8) (21.9) (50.9)
52-week high/low C$0.6/C$0.2
*% relative to local index
Key management
Deborah Rathgen Executive Chair